| 產品名稱 | WPE1-NB26-64 |
|---|---|
| 商品貨號 | B186290 |
| Organism | Homo sapiens, human |
| Tissue | prostate peripheral zone |
| Cell Type | epithelialHPV-18 transfected |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level | 2 cells containing human HPV-18 viral DNA sequences
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | hepatitis |
| Age | 54 |
| Gender | male |
| Ethnicity | Caucasian |
| Applications | WPE1-NB26-64 and WPE1-NB26-65 (ATCC CRL-2890) were derived from a subcutaneous tumor in a nude mouse injected with WPE1-NB26 (ATCC CRL-2852). They secrete matrix metalloproteinases 9 and 2 (MMP-9 and MMP-2) into the culture medium while the parent line produces barely detectable levels. WPE1-NB26-65 secretes 40% higher levels of MMP-2 than WPE1-NB26-64. [PubMed: 16471037]
WPE1-NB26 cells belong to a family of cell lines, referred to as the MNU cell lines, which are all derived from RWPE-1 (ATCC CRL-11609) cells after exposure to MNU. The MNU cell lines, in order of increasing malignancy are: WPE1-NA22 (ATCC CRL-2849), WPE1-NB14 (ATCC CRL-2850), WPE1-NB11 (ATCC CRL-2851) and WPE1-NB26 (ATCC CRL-2852). |
| Storage Conditions | liquid nitrogen vapor phase |
| Images |  |
| Derivation | WPE1-NB26-64 and WPE1-NB26-65 (ATCC CRL-2890) were derived from a subcutaneous tumor in a nude mouse injected with WPE1-NB26 (ATCC CRL-2852). They secrete matrix metalloproteinases 9 and 2 (MMP-9 and MMP-2) into the culture medium while the parent line produces barely detectable levels. WPE1-NB26-65 secretes 40% higher levels of MMP-2 than WPE1-NB26-64. [PubMed: 16471037]
WPE1-NB26 cells belong to a family of cell lines, referred to as the MNU cell lines, which are all derived from RWPE-1 (ATCC CRL-11609) cells after exposure to MNU. The MNU cell lines, in order of increasing malignancy are: WPE1-NA22 (ATCC CRL-2849), WPE1-NB14 (ATCC CRL-2850), WPE1-NB11 (ATCC CRL-2851) and WPE1-NB26 (ATCC CRL-2852).
The WPE1-NB26-64 and WPE1-NB26-65 cell lines show an increase in anchorage-dependent growth and invasive ability as compared to the parent WPE1-NB26.
|
| Clinical Data | male Caucasian 54 |
| Antigen Expression | kallikrein 3 (KLK3; prostate specific antigen (PSA), upon exposure to androgen |
| Receptor Expression | androgen receptor, expressed (upregulated upon exposure to androgen) |
| Genes Expressed | kallikrein 3 (KLK3; prostate specific antigen (PSA), upon exposure to androgen |
| Tumorigenic | YES |
| Comments | WPE1-NB26-64 and WPE1-NB26-65 (ATCC CRL-2890) were derived from a subcutaneous tumor in a nude mouse injected with WPE1-NB26 (ATCC CRL-2852). They secrete matrix metalloproteinases 9 and 2 (MMP-9 and MMP-2) into the culture medium while the parent line produces barely detectable levels. WPE1-NB26-65 secretes 40% higher levels of MMP-2 than WPE1-NB26-64. [PubMed: 16471037]
WPE1-NB26 cells belong to a family of cell lines, referred to as the MNU cell lines, which are all derived from RWPE-1 (ATCC CRL-11609) cells after exposure to MNU. The MNU cell lines, in order of increasing malignancy are: WPE1-NA22 (ATCC CRL-2849), WPE1-NB14 (ATCC CRL-2850), WPE1-NB11 (ATCC CRL-2851) and WPE1-NB26 (ATCC CRL-2852).
The WPE1-NB26-64 and WPE1-NB26-65 cell lines show an increase in anchorage-dependent growth and invasive ability as compared to the parent WPE1-NB26.
|
| Complete Growth Medium | The base medium for this cell line is provided by Invitrogen (GIBCO) as part of a kit: Keratinocyte Serum Free Medium (K-SFM), Kit Catalog Number 17005-042. This kit is supplied with each of the two additives required to grow this cell line (bovine pituitary extract (BPE) and human recombinant epidermal growth factor (EGF).
To make the complete growth medium, you will need to add the following components to the base medium:
|
| Subculturing | Protocol: Volumes used in this protocol are for 75 sq cm flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:5 is recommended
Medium Renewal: Every 48 hours
Note: Subculture cells before they reach confluence. Do not allow cells to become confluent. |
| Cryopreservation | Freeze medium: Complete growth medium described above supplemented with 15% fetal bovine serum and 10% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions | Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37°C |
| STR Profile | Amelogenin: X,Y CSF1PO: 13 D13S317: 8,14 D16S539: 9,11 D5S818: 12,15 D7S820: 10,11 THO1: 8 TPOX: 8,11 vWA: 14,18 |
| Population Doubling Time | about 19 hours |
| Name of Depositor | MM Webber |
| Year of Origin | 1994 |
| References | Bello D, et al. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 18: 1215-1223, 1997. PubMed: 9214605 Webber MM, et al. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 18: 1225-1231, 1997. PubMed: 9214606 Webber MM, et al. Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Carcinogenesis 17: 1641-1646, 1996. PubMed: 8761420 Okamoto M, et al. Interleukin-6 and epidermal growth factor promote anchorage-independent growth of immortalized human prostatic epithelial cells treated with N-methyl-N-nitrosourea. Prostate 35: 255-262, 1998. PubMed: 9609548 Webber MM, et al. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. Prostate 29: 386-394, 1996. PubMed: 8977636 Webber MM, et al. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 30: 58-64, 1997. PubMed: 9018337 Webber MM, et al. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications. Prostate 30: 136-142, 1997. PubMed: 9051152 Kremer R, et al. ras Activation of human prostate epithelial cells induces overexpression of parathyroid hormone-related peptide. Clin. Cancer Res. 3: 855-859, 1997. PubMed: 9815759 Jacob K, et al. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. Cancer Res. 59: 4453-4457, 1999. PubMed: 10485497 Achanzar WE, et al. Cadmium induces c-myc, p53, and c-jun expression in normal human prostate epithelial cells as a prelude to apoptosis. Toxicol. Appl. Pharmacol. 164: 291-300, 2000. PubMed: 10799339 Achanzar WE, et al. Cadmium-induced malignant transformation of human prostate epithelial cells. Cancer Res. 61: 455-458, 2001. PubMed: 11212230 Bello-DeOcampo D, et al. Laminin-1 and alpha6beta1 integrin regulate acinar morphogenesis of normal and malignant human prostate epithelial cells. Prostate 46: 142-153, 2001. PubMed: 11170142 Webber MM, et al. Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression. Prostate 47: 1-13, 2001. PubMed: 11304724 Quader ST, et al. Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model. Mutat. Res. 496: 153-161, 2001. PubMed: 11551491 Webber MM, et al. A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis 20: 1185-1192, 1999. PubMed: 10383888 Bello-DeOcampo D, et al. The role of alpha 6 beta 1 integrin and EGF in normal and malignant acinar morphogenesis of human prostatic epithelial cells. Mutat. Res. 480-481: 209-217, 2001. PubMed: 11506815 upregulated upon exposure to androgen Webber MM, et al. Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). Clin. Exp. Metastasis 17: 255-263, 1999. PubMed: 10432011 Sharp RM, et al. N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention. Mutat. Res. 496: 163-170, 2001. PubMed: 11551492 Carruba G, et al. Regulation of cell-to-cell communication in non-tumorigenic and malignant human prostate epithelial cells. Prostate 50: 73-82, 2002. PubMed: 11816015 Achanzar WE, et al. Altered apoptotic gene expression and acquired apoptotic resistance in cadmium-transformed human prostate epithelial cells. Prostate 52: 236-244, 2002. PubMed: 12111698 Carruba G, et al. Intercellular communication and human prostate carcinogenesis. Ann. N.Y. Acad. Sci. 963: 156-168, 2002. PubMed: 12095941 Saladino F, et al. Connexin expression in nonneoplastic human prostate epithelial cells. Ann. N.Y. Acad. Sci. 963: 213-217, 2002. PubMed: 12095946 Hegarty PK, et al. Effects of cyclic stretch on prostatic cells in culture. J. Urol. 168: 2291-2295, 2002. PubMed: 12394777 Lugassy C, et al. Human melanoma cell migration along capillary-like structures in vitro: a new dynamic model for studying extravascular migratory metastasis. J. Invest. Dermatol. 119: 703-704, 2002. PubMed: 12230517 Brambila EM, et al. Chronic arsenic-exposed human prostate epithelial cells exhibit stable arsenic tolerance: mechanistic implications of altered cellular glutathione and glutathione S-transferase. Toxicol. Appl. Pharmacol. 183: 99-107, 2002. PubMed: 12387749 Achanzar WE, et al. Inorganic arsenite-induced malignant transformation of human prostate epithelial cells. J. Natl. Cancer Inst. 94: 1888-1891, 2002. PubMed: 12488483 Rivette AS, et al. Selection of cell lines with enhanced invasive phenotype from xenografts of the human prostate cancer cell line WPE1-NB26. J. Exp. Ther. Oncol. 5: 111-123, 2005. PubMed: 16471037 |
| 梅經理 | 17280875617 | 1438578920 |
| 胡經理 | 13345964880 | 2438244627 |
| 周經理 | 17757487661 | 1296385441 |
| 于經理 | 18067160830 | 2088210172 |
| 沈經理 | 19548299266 | 2662369050 |
| 李經理 | 13626845108 | 972239479 |
